While the RNI for maintenance is only 1.5 g daily, therapeutic oral doses typically range from: 50-150 g daily for mild deficiency prevention in at-risk groups 1,000-2,000 g daily for treating confirmed deficiency without malabsorption Some formulations contain up to 5,000 g, though there is no proven additional benefit over 1,000-2,000 g for most patients The reason for this dosage discrepancy lies in absorption efficiency
This advanced protocol pairs BPC-157 with TB-500 (Thymosin Beta-4), two regenerative peptides that work together to create a powerful, whole-body healing effect
Research has examined its role in: 3-adrenergic receptor upregulation and adipose tissue sensitisation studies Lipolysis stimulation and plasma glycerol elevation in adipocyte models Lipogenesis inhibition and fat accumulation prevention in diet-induced obesity models Fat oxidation and energy expenditure pathway research Metabolic flexibility and substrate oxidation studies in obese murine models Cartilage regeneration and intra-articular joint biology in osteoarthritis models Safety pharmacology genotoxicity, bioavailability, and plasma kinetics profiling Comparative hGH fragment activity studies alongside AOD9401 and native hGH AOD9604 and Adipose Tissue Research In obese Zucker rats treated with oral AOD9604 at 500 g/kg body weight for 19 days, over 50% reduction in body weight gain was observed compared to controls, accompanied by significantly increased lipolytic activity in adipose tissue
A CBC or BMP are often first line tests for identifying underlying health issues like anemia or diabetes but dont offer a complete look into your overall health
Calms inflammation without suppressing repair Unlike NSAIDs and steroids which block inflammation but impair collagen quality BPC-157 modulates the inflammatory response while allowing tissue rebuilding to proceed (anti-inflammatory modulation)
Testing - Over 25 different standards must be met for each product - ensuring purity and potency and that they are free of any bacterial agents
